The aim of this study is to compare the effectiveness of two treatments for severe / very severe COPD patients: one, conventional medicine based on 2013 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines; the other, TCM treatments and conventional medicine, which have been evaluated and have certain effect.

开始日期2014-10-01

申办/合作机构

Henan University of Traditional Chinese Medicine

NCT01836016 / Unknown status临床3期IIT

Comparison of Conventional Medicine, TCM Treatment and Combination of Both Conventional Medicine and TCM Treatment for Patients With Chronic Obstructive Pulmonary Disease: A Randomized Comparative Effectiveness Research Trial

The aim of this study is to compare the effectiveness and economic evaluation of three treatments for Chronic Obstructive Pulmonary Disease (COPD) patients: one, conventional medicine based on 2011 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines; another, TCM treatments, which have been evaluated and have certain effect; and finally, combination of both conventional medicine and TCM treatment, then determine which treatment is the most suitable for COPD patients.

开始日期2013-05-01

申办/合作机构

Henan University of Traditional Chinese Medicine

100 项与益气滋肾颗粒相关的临床结果

登录后查看更多信息

100 项与益气滋肾颗粒相关的转化医学

登录后查看更多信息

100 项与益气滋肾颗粒相关的专利（医药）

登录后查看更多信息

项与益气滋肾颗粒相关的文献（医药）

2024-10-01·Heliyon

Efficacy and safety of Yishen Huashi granules combined with conventional therapy in the treatment of diabetic kidney disease: A systematic review and meta-analysis

Review

作者: Xu, Jian ; Chen, Jinying ; Zhu, Zexin ; Liu, Shilin ; Nan, Zheng ; Xu, Shengxian ; Song, Chaoqun ; Dai, Bo ; Lin, Minghao ; Chen, Yanxu ; Liu, Zhenru ; Bao, Pengjie ; Yang, Huhu

Ethnopharmacological relevanceDiabetic kidney disease(DKD) is a complication of diabetes. If not treated in time, it will lead to severe glomerular damage, causing irreversible damage, and ultimately may lead to uremia and even death. Yishen Huashi Granule (YSHS) is a Chinese patent medicine for treating DKD by invigorating the spleen and removing dampness, which has shown a good curative effect.Aim of the studyThis study systematically evaluated the clinical efficacy and blood biochemical improvement of YSHS combined with conventional therapy (CT) in treating DKD.Materials and methodsBy August 2024, four English databases (PubMed, Web of Science, the Cochrane Library, and Embase) and four Chinese databases (China National Knowledge Infrastructure (CNKI), Wanfang Database (WF), China Biological Medicine Database (CBM), and China Science and Technology Journal Database (VIP)) were searched to screen literature, extract information, and evaluate quality according to inclusion and exclusion criteria. The language of these literature is limited to Chinese and English, but not limited to published sources. Meta-analysis and bias analysis were performed using Steata 16 software and Review Manager 5.3 software. The bias risk tool in the Cochrane Handbook was used to assess the quality of the literature. At 95 % confidence interval (CI), relative risk (RR) and Cohen's d were used for the categorical and continuous variables, respectively. To evaluate heterogeneity, the Q test and I² statistics were employed within a random-effects model framework.ResultsA total of 28 randomized controlled trials (RCTs) comprising 2416 patients were included in this study. There were 1200 patients in the control group and 1216 in the treatment group. Compared with CT, combined YSHS therapy is more effective at improving clinical efficiency rate [RR(95 % confidence interval (CI)) = 1.26(1.21, 1.32), I² = 15.83 %], renal function (urinary albumin excretion rate [SMD(95%CI) = -1.72(-2.27, -1.17), I² = 95.5 %], 24-h quantitative urine protein level [SMD(95%CI) = -1.50(-2.51, -0.50), I² = 95.52 %], blood urea nitrogen [SMD(95%CI) = -1.13(-1.46, -0.81), I² = 89.81 %], SCr [SMD(95%CI) = -2.34(-3.36, -1.32), I² = 97.90 %], eGFR [SMD(95%CI) = 0.50(0.18,0.82), I² = 51.51 %]), glucose metabolism levels (FBG [SMD(95%CI) = -0.50(-0.87, -0.14), I² = 89.67 %], 2hPG [SMD(95%CI) = -0.83(-1.39, -0.26), I² = 87.11 %], HbA1c [SMD(95%CI) = -0.79(-1.74, -0.15), I² = 94.6 %]), lipid metabolism levels (TC [SMD(95%CI) = -1.53(-2.32, -0.75), I² = 95.49 %], TG [SMD(95%CI) = -0.96(-1.08, -0.77), I² = 86.05 %], LDL-C [SMD(95%CI) = -1.25(-1.81, -0.69), I² = 90.56 %], HDL-C [SMD(95%CI) = 0.71(0.43, 0.98), I² = 55.92 %]), oxidative stress indicators (SOD [SMD(95%CI) = 6.00(2.77, 9.24, I² = 99.01 %], MDA [SMD(95%CI) = -2.81(-3.58, -2.05), I² = 89.64 %]), ALB [SMD(95%CI) = 1.01(0.63, -1.39), I² = 68.89 %], vWF [SMD(95%CI) = -0.84(-1.08, -0.60), I² = 0 %], ET-1 [SMD(95%CI) = -0.89(-1.13, -0.65), I² = 0 %], and MAP [SMD(95%CI) = -1.76(-3.26, -0.25), I² = 94.05 %]. The incidence of adverse reactions in YSHS combination therapy was not high [SMD(95%CI) = 0.99(0.97, 1.02), I² = 0.03 %].ConclusionThe meta-analysis revealed that YSHS combined with CT therapy is superior to CT in improving clinical outcomes, renal function, glucose metabolism, lipid metabolism, and oxidative stress. Yishen Huashi granules is more effective and safer for Diabetic kidney disease treatment.

2024-03-20·Nan fang yi ke da xue xue bao = Journal of Southern Medical University

[Jianpi Zishen granule inhibits podocyte autophagy in systemic lupus erythematosus: a network pharmacology and clinical study].

Article

作者: Chen, J ; Li, M ; Huang, C

OBJECTIVETo explore the therapeutic mechanism of Jianpi Zishen (JPZS) granules for systemic lupus erythematosus(SLE) in light of podocyte autophagy regulation.METHODSTCMSP, GeneCards, OMIM, and TTD databases were used to obtain the targets of JPZS granules, SLE, and podocyte autophagy. The protein-protein interaction network was constructed using Cytoscape, and the key active ingredients and targets were screened for molecular docking. In the clinical study, 46 patients with SLE were randomized into two groups to receive baseline treatment with prednisone acetate and mycophenolate mofetil (control group) and additional treatment with JPZS granules (observation group) for 12 weeks, with 10 healthy volunteers as the healthy control group. Urinary levels of nephrin and synaptopodin of the patients were detected with ELISA. Western blotting was performed to determine peripheral blood levels of p-JAK1/JAK1, p-STAT1/STAT1, LC3II/LC3I, and p62 proteins of the participants.RESULTSFour key active ingredients and 5 core target genes (STAT1, PIK3CG, MAPK1, PRKCA, and CJA1) were obtained, and enrichment analysis identified the potentially involved signaling pathways including AGE-RAGE, JAK/STAT, EGFR, and PI3K/Akt. Molecular docking analysis showed that STAT1 was the most promising target protein with the highest binding activity, suggesting its role as an important mediator for signal transduction after JPZS granule treatment. In the 43 SLE patients available for analysis, treatment with JPZS granule significantly reduced serum levels of p-JAK1/JAK1, p-STAT1/STAT1, and LC3II/LC3I (P < 0.05 or 0.01), increased the protein level of P62 (P < 0.05), and reduced urinary levels of nephrin and synaptopodin (P < 0.05).CONCLUSIONThe therapeutic effect of JPZS granules on SLE is mediated probably by coordinated actions of quercetin, kaempferol, β-sitosterol, and isorhamnetin on their target gene STAT1 to inhibit the JAK/STAT pathway, thus suppressing autophagy and alleviating podocyte injuries in SLE.

2023-09-01·Alternative therapies in health and medicine

Efficacy and Safety of Acupuncture Combined with Yishen Granule in Elderly Adults with Mild Cognitive Impairment: A Multicenter, Randomized Controlled Trial.

Article

作者: Xu, Jian ; Zhao, Zhenghao ; Zhang, Jie ; Li, Yixia ; Li, Zhimin ; Xu, Shifen ; Wang, Yuxia ; Li, Ou ; Sha, Zhongwei ; Li, Nana

ObjectiveMild cognitive impairment (MCI) is a clinical disease that is prevalent in the elderly. Traditional Chinese herbs (TCHs) and acupuncture are valuable therapeutic options for MCI. This study aimed to assess the efficacy and safety of acupuncture and Yishen Granule (YSG) in restoring cognitive function in elderly patients with MCI.MethodsA multicenter, randomized, double-blind, parallel-group, controlled trial (8-week intervention) was conducted at two tertiary hospitals in Shanghai, China. A total of 120 participants were randomly divided into four groups (n = 30 per group): A, acupuncture with YSG; B, acupuncture with placebo herbal medicine; C, sham acupuncture with YSG; D, sham acupuncture with placebo herbal medicine. The primary outcome was a change in Montreal Cognitive Assessment (MoCA), while the secondary outcome was to evaluate improvement in the Mini-Mental State Examination (MMSE). Assessments were conducted at baseline and weeks 4 and 8.ResultsOf the 120 patients (69.17 ± 6.57 years; 71 women [59.17%] and 49 men [40.83%]) included in the study, 106 (88.33%) completed the study. Two-way repeated measures ANOVA showed that the MoCA and MMSE scores in group A were significantly different from those in group D at week 4 (P < .05). At week 8, the MoCA and MMSE scores in groups A, B, and C were significantly improved compared with those in group D (P < .001 for all), and the delayed recall score in group A was significantly greater than those in groups B and C (P < .05). Acupuncture and YSG were well tolerated and safe, and no serious adverse events were reported.ConclusionsAcupuncture, YSG, and the combination of both improved cognitive function, with the combined therapy being the most effective, which can be beneficial in preventing dementia and improving the quality of life of the elderly.

100 项与益气滋肾颗粒相关的药物交易

登录后查看更多信息